Veradigm Sees FY23 Revenue $608M-$622M
Portfolio Pulse from Benzinga Newsdesk
Veradigm, a healthcare information technology solutions provider, has projected its revenue for the fiscal year 2023 to be between $608 million and $622 million.

January 10, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allscripts Healthcare Solutions, Inc. (MDRX), the parent company of Veradigm, may see a positive impact on its stock price following Veradigm's revenue forecast for FY23.
Veradigm's revenue forecast is a direct reflection of its business performance and growth prospects. As a subsidiary of Allscripts Healthcare Solutions, Inc. (MDRX), this positive outlook is likely to be viewed favorably by investors and could lead to an increase in MDRX's stock price in the short term. The forecasted revenue range suggests a strong year ahead for Veradigm, which could contribute significantly to the parent company's overall financial health.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80